Targeted agents, such as sorafenib, pazopanib, and sunitinib, which inhibit vascular endothelial growth factor and its receptors, have been utilized in the treatment of ccRCC, and inhibition of rapamycin complex 1 by everolimus and temsirolimus has shown some success in improving the prognosis of patients with advanced stage [33, 34]. This evidence concerns the gene VEGFA and nonpapillary renal cell carcinoma.